for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shin Nippon Biomedical Laboratories Ltd

2395.T

Latest Trade

828.00JPY

Change

18.00(+2.22%)

Volume

545,500

Today's Range

804.00

 - 

834.00

52 Week Range

606.00

 - 

980.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
810.00
Open
812.00
Volume
545,500
3M AVG Volume
7.12
Today's High
834.00
Today's Low
804.00
52 Week High
980.00
52 Week Low
606.00
Shares Out (MIL)
41.63
Market Cap (MIL)
33,722.24
Forward P/E
--
Dividend (Yield %)
0.37

Next Event

Q3 2020 Shin Nippon Biomedical Laboratories Ltd Earnings Release

Latest Developments

More

Shin Nippon Biomedical Laboratories to sell unit for 1 bln yen

Shin Nippon Biomedical Laboratories says 2016 dividend payment date is Aug. 16

Shin Nippon Biomedical Laboratories to cut stake in SNBL Clinical Pharmacology Center, Inc. to 67.4 pct from 100 pct

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shin Nippon Biomedical Laboratories Ltd

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.

Industry

Biotechnology & Drugs

Contact Info

28F, St Luke's Tower, 8-1, Akashi-cho

+81.3.55655001

https://www.snbl.co.jp/

Executive Leadership

Ryoichi Nagata

Chairman of the Board, President, Group Chief Executive Officer, Chairman of Subsidiary, Representative Director

Koichiro Fukuzaki

Vice Chairman of the Board

Takeshi Yamakawa

Chief Executive Officer of Subsidiary, Director

Ken Takanashi

Chief Operating Officer, Vice President, Representative Director

Shuichi Kanazashi

Managing Director, President of TR Business Company

Key Stats

Price To Earnings (TTM)
22.13
Price To Sales (TTM)
2.30
Price To Book (MRQ)
1.40
Price To Cash Flow (TTM)
11.89
Total Debt To Equity (MRQ)
64.42
LT Debt To Equity (MRQ)
16.99
Return on Investment (TTM)
4.61
Return on Equity (TTM)
2.96

Latest News

Latest News

BRIEF-Shin Nippon Biomedical Laboratories to cut stake in SNBL Clinical Pharmacology Center, Inc. to 67.4 pct from 100 pct

* Says the co to cut stake in the U.S.-based unit, SNBL Clinical Pharmacology Center, Inc., to 67.4 percent from 100 percent

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up